100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
Summary Cell Growth and Differentiation - translational (MM1TR) €6,39   In winkelwagen

Samenvatting

Summary Cell Growth and Differentiation - translational (MM1TR)

 7 keer bekeken  0 keer verkocht

Comprehensive up-to-date summary of the first-year MMD course Cell Growth and Differnetiation - Translational (MM1TR). Save yourself a huge amount of time studying for this exam by using this summary!

Voorbeeld 3 van de 20  pagina's

  • 24 oktober 2023
  • 20
  • 2022/2023
  • Samenvatting
Alle documenten voor dit vak (1)
avatar-seller
lisaverhoeven80
Summary cell growth & differentiation
– Translational: developmental
disorders and malignancies




1

,Chapter 1 Blood cell disorders
Hematopoiesis is the development of blood cells  takes place in the bone marrow
 Hematopoietic stem cells (HSCs) are present in the bone marrow give rise to all blood cells  differentiate in
the BM into progenitor cells
 Differentiation is steered by growth factors  extrinsic
 In combination with transcription factors  stem cell intrinsic
o Intrinsic factors might change over time  might be the reason why children in average
develop lymphoid leukaemia more often than myeloid leukaemia than elderly
 Progenitor cells  referred to as ‘blasts’ remain within the BM and only enter the periphery when
fully differentiated
o Lymphoid
o Myeloid
 HSCs have the capacity to self-renew  very slow division so more Quiescent
 Multi-hit model: mutations passed on to daughter cells
 With each SC division the number of mutations increases
 Commonly used marker for blasts and HSCs is CD34
 Differentiation is tightly regulated  mutations can cause disbalance
 Many genes involved
 Driver mutations: almost all of these are in signalling regulation




Leukaemia vs myelodysplastic syndrome
A quite severe and common developmental disorder in hematopoiesis is leukemia:
 Leukemia is the accumulation of immature cells in the BM  blasts do not leave the BM
 Upregulated proliferation  growth factor independent
 Decreased apoptosis
 And a block in differentiation  leads to accumulation of blasts
 Acute when >20% of cells in the BM are blasts

Myelodysplastic syndrome: we speak of myelodysplastic syndrome when the blood cells have an abnormal shape
but they do differentiate
 Indolent MDS: So unlike in leukaemia cells differentiate
 Aggressive MDS: And with aggressive MDS the cells look dysplastic on top of their blocked differentiation
 Thus can develop into leukaemia at a later stage  we speak of this when differentiation gets
blocked and blasts start accumulating
 Affected lineage differs per patient  hence symptoms differ per patient

Both leukaemia (AML) and myelodysplastic syndrome (MDS) have a higher incidence amongst the elderly which
largely impacts treatment and prognosis.

2

, Development of leukaemia
Mutations are acquired due to carcinogenic agents, and naturally during cell division  all mutations in HSCs are
passed on to daughter cells
 Development of leukaemia is a multi-hit process  multiple driver mutations required to acquire the cancer
hallmarks
 These mutations are in genes that regulate the balance between proliferation and apoptosis  give
the cell a growth advantage
o Positive selection leads to mutation co-occurrence
 Causes clonal expansion
 CHIPs might increase the risk for leukaemia because they can be malignant in combination with
other mutations
 Full blown leukaemia is a combination of mutations in 2-3 genes from different categories:
 I: growth factor receptors
 II: signal transduction molecules
 III: gene expression regulation
o TFs
o Epigenetic regulators
o RNA splicing factors
o Chromatin organisation
 IV: apoptosis

Enzymes involved in DNA (de)methylation are often mutated in AML  hypermethylation of promoters for tumour-
suppressor genes or demethylation of proto-oncogenes
 DNMT(3a): copy methylation profile after division  hyperactivity
 Hypomethylating agents: Azacitidine and decitabine are cytosine analogues  incorporated at C-
sites but cannot be methylated
 TET(2) proteins: operate in active demethylation  need α-ketogluterate as a substrate

 IDH1/2: convert α-KG into α-HG
 Inhibitors of IDH1/2 increase α-KG levels




3

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper lisaverhoeven80. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €6,39. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 67474 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€6,39
  • (0)
  Kopen